A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorZhejiang University
About this trial
This study aims to evaluate the safety, tolerability, and efficacy of HRS-2329 in combination with other anti-tumor therapies in participants with advanced pancreatic cancer harboring RAS mutations or amplifications.
Eligibility criteria
Qualifiers
Age ≥ 18 years.
Histopathologically confirmed locally advanced or metastatic pancreatic adenocarcinoma (originating from pancreatic ductal epithelium) that is not amenable to curative therapy.
RAS mutation or amplification detected in tumor tissue or blood (by RAS testing).
For cohort HRS-2329-A: at least one line of standard systemic therapy in the advanced setting;
Disqualifiers
Prior treatment with drugs similar to the investigational product.
Known presence of central nervous system (CNS) metastases.
Acute or chronic pancreatitis requiring clinical intervention.
Gastrointestinal disorders that may affect drug administration/absorption, including but not limited to dysphagia, malabsorption syndrome, refractory nausea, vomiting, or diarrhea, Crohn's disease, and ulcerative colitis.
Trial design
Treatments tested in this trial
- HRS-2329 Tablet
- Nimotuzumab
- HS-20093
- Adebrelimab
Treatment groups
80 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov